Inventaire - your friends and communities are your best library

Antibodies to watch in 2010

author

Janice M. Reichert

2000 -

published in: Monoclonal Antibodies

date of publication: 2010-01-16

main subject: antibody

Cites articles 50

Date

Title

Authors

2009-03-01

Insulin-like growth factor receptor type I as a target for cancer therapy
2009-01-01

New challenges to medicare beneficiary access to mAbs
2009-09-01

Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy

Sabrina Oliveira, Raymond M. Schiffelers, Rob C Roovers
2009-09-01

Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations
2009-09-01

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

Michelle A. Petri, Joan T Merrill, Ellen M Ginzler
2009-09-01

Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer

Hossein Borghaei, R Katherine Alpaugh, Corey J Langer
2009-06-09

The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases
2009-05-14

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

Vicki Seyfert-Margolis, Jennifer M Puck, Kevan C Herold, Carla J Greenbaum
2009-05-01

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

Munther A. Khamashta
2009-06

CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma
2009-07

Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates

Gerald W. Fischer
2009-04-03

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

Gabriel N Hortobagyi
2009-05

Anti-CD3 mAbs for treatment of type 1 diabetes
2009-03-05

Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults

Gerald W. Fischer
2009-02-06

Ipilimumab: controversies in its development, utility and autoimmune adverse events
2009-04-20

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

George R Blumenschein
2008-12-01

Monoclonal antibodies as innovative therapeutics
2008-11-01

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

Robert J. Lutz
2008-10-01

The use of galiximab in non-Hodgkin lymphoma
2008-10-01

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin

Brian G. Feagan, Richard N. Fedorak
2008-05-01

Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer

Sandra M. Swain
2008-04-21

RETRACTED: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility
2008-03-16

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

Amy D. Klion, Hans-Uwe Simon, Jean Emmanuel Kahn, Gerald J Gleich, Florence E Roufosse, Johannes Ring, Marc E. Rothenberg, Lanny J Rosenwasser
2008-02-20

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

Henry Seth Friedman, Darell D. Bigner, Annick Desjardins, Allan Friedman, David A Reardon, Roger E McLendon, Jeremy N Rich, R. Edward Coleman, Jennifer J Quinn, James J Vredenburgh, James H. Herndon, Michael R Zalutsky, Gamal Akabani, Charles N Pegram, Jeanette M Dowell, Xiao-Guang Zhao
2008-11-17

Phase I/II study of ipilimumab for patients with metastatic melanoma.
2008-09-01

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
2008-02-01

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial
2007-11-13

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
2007-11-02

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

Steven Rosenberg
2007-08-15

Interleukin-12, interleukin-23, and psoriasis: current prospects
2007-03-09

Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha

Lloyd J. Old
2007-08-01

Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia

Ian W. Flinn

Article - wd:Q33688243

Welcome to Inventaire

the library of your friends and communities

learn more